{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:30:23Z","timestamp":1795015823724,"version":"4.10.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T00:00:00Z","timestamp":1682380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010903","name":"National Science Foundation of China | Key Programme","doi-asserted-by":"publisher","award":["No.2019YFC1316203"],"award-info":[{"award-number":["No.2019YFC1316203"]}],"id":[{"id":"10.13039\/501100010903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010903","name":"National Science Foundation of China | Key Programme","doi-asserted-by":"publisher","award":["No.2019YFC1316204"],"award-info":[{"award-number":["No.2019YFC1316204"]}],"id":[{"id":"10.13039\/501100010903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81873434"],"award-info":[{"award-number":["No.81873434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention have shown efficacy in patients with T-cell acute lymphoblastic leukemia (ALL). Here we launched a phase I trial to explore differences between autologous and allogeneic anti-CD7 CAR-T therapies in T-cell ALL and lymphoma. Ten patients were treated and 5 received autologous CAR-T therapies. No dose-limiting toxicity or neurotoxicity was observed. Grade 1\u20132 cytokine release syndrome occurred in 7 patients, and grade 3 in 1 patient. Grade 1\u20132 graft-versus-host diseases were observed in 2 patients. Seven patients had bone marrow infiltration, and 100% of them achieved complete remission with negative minimal residual disease within one month. Two-fifths of patients achieved extramedullary or extranodular remission. The median follow-up was 6 (range, 2.7\u201314) months and bridging transplantation was not administrated. Patients treated with allogeneic CAR-T cells had higher remission rate, less recurrence and more durable CAR-T survival than those receiving autologous products. Allogeneic CAR-T cells appeared to be a better option for patients with T-cell malignancies.<\/jats:p>","DOI":"10.1038\/s41408-023-00822-w","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T23:36:32Z","timestamp":1682379392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies"],"prefix":"10.1038","volume":"13","author":[{"given":"Yinqiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiwen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xindi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongpei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-309X","authenticated-orcid":false,"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2815-4568","authenticated-orcid":false,"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-2443","authenticated-orcid":false,"given":"Heng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,25]]},"reference":[{"key":"822_CR1","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507\u201317.","journal-title":"N Engl J Med"},{"key":"822_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517\u201328.","journal-title":"Lancet."},{"key":"822_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"822_CR4","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","volume":"129","author":"RA Gardner","year":"2017","unstructured":"Gardner RA, Finney O, Annesley C, Brakke H, Summers C, Leger K, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322\u201331.","journal-title":"Blood."},{"key":"822_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.blre.2017.08.006","volume":"32","author":"E Vadillo","year":"2018","unstructured":"Vadillo E, Dorantes-Acosta E, Pelayo R, Schnoor M. T cell acute lymphoblastic leukemia (T-ALL): New insights into the cellular origins and infiltration mechanisms common and unique among hematologic malignancies. Blood Rev. 2018;32:36\u201351.","journal-title":"Blood Rev"},{"key":"822_CR6","doi-asserted-by":"publisher","first-page":"E245","DOI":"10.1002\/ajh.25896","volume":"95","author":"B Samra","year":"2020","unstructured":"Samra B, Alotaibi AS, Short NJ, Khoury JD, Ravandi F, Garris R, et al. Outcome of adults with relapsed\/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Am J Hematol. 2020;95:E245\u2013E7.","journal-title":"Am J Hematol"},{"key":"822_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41568-020-0247-0","volume":"20","author":"D Fiore","year":"2020","unstructured":"Fiore D, Cappelli LV, Broccoli A, Zinzani PL, Chan WC, Inghirami G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20:323\u201342.","journal-title":"Nat Rev Cancer"},{"key":"822_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL. Peripheral T-cell lymphoma, not otherwise specified. Blood. 2017;129:1103\u201312.","journal-title":"Blood."},{"key":"822_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"M Dreyling","year":"2013","unstructured":"Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857\u201377.","journal-title":"Ann Oncol"},{"key":"822_CR10","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","volume":"34","author":"S Chiba","year":"2020","unstructured":"Chiba S, Sakata-Yanagimoto M. Advances in understanding of angioimmunoblastic T-cell lymphoma. Leukemia. 2020;34:2592\u2013606.","journal-title":"Leukemia."},{"key":"822_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41392-022-00898-z","volume":"7","author":"Z Dai","year":"2022","unstructured":"Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K, et al. T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. 2022;7:85.","journal-title":"Signal Transduct Target Ther"},{"key":"822_CR12","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13045-021-01178-z","volume":"14","author":"J Shi","year":"2021","unstructured":"Shi J, Zhang Z, Cen H, Wu H, Zhang S, Liu J, et al. CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. J Hematol Oncol. 2021;14:162.","journal-title":"J Hematol Oncol"},{"key":"822_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13046-022-02421-2","volume":"41","author":"X Wang","year":"2022","unstructured":"Wang X, Yu X, Li W, Neeli P, Liu M, Li L, et al. Expanding anti-CD38 immunotherapy for lymphoid malignancies. J Exp Clin Cancer Res. 2022;41:210.","journal-title":"J Exp Clin Cancer Res"},{"key":"822_CR14","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","volume":"77","author":"D Campana","year":"1991","unstructured":"Campana D, van Dongen JJ, Mehta A, Coustan-Smith E, Wolvers-Tettero IL, Ganeshaguru K, et al. Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. Blood. 1991;77:1546\u201354.","journal-title":"Blood."},{"key":"822_CR15","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.4049\/jimmunol.150.5.2081","volume":"150","author":"U Reinhold","year":"1993","unstructured":"Reinhold U, Abken H, Kukel S, Moll M, M\u00fcller R, Oltermann I, et al. CD7- T cells represent a subset of normal human blood lymphocytes. J Immunol. 1993;150:2081\u20139.","journal-title":"J Immunol"},{"key":"822_CR16","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4049\/jimmunol.152.2.517","volume":"152","author":"H Rabinowich","year":"1994","unstructured":"Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol. 1994;152:517\u201326.","journal-title":"J Immunol"},{"key":"822_CR17","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.4049\/jimmunol.160.12.5749","volume":"160","author":"DM Lee","year":"1998","unstructured":"Lee DM, Staats HF, Sundy JS, Patel DD, Sempowski GD, Scearce RM, et al. Immunologic characterization of CD7-deficient mice. J Immunol. 1998;160:5749\u201356.","journal-title":"J Immunol"},{"key":"822_CR18","doi-asserted-by":"publisher","first-page":"e149819","DOI":"10.1172\/jci.insight.149819","volume":"6","author":"MY Kim","year":"2021","unstructured":"Kim MY, Cooper ML, Jacobs MT, Ritchey JK, Hollaway J, Fehniger TA, et al. CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy. JCI Insight. 2021;6:e149819.","journal-title":"JCI Insight"},{"key":"822_CR19","first-page":"321","volume":"140","author":"P Lu","year":"2022","unstructured":"Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321\u201334.","journal-title":"Blood."},{"key":"822_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","volume":"32","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhou Y, Zhang M, Zhao H, Wei G, Ge W, et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 2022;32:995\u20131007.","journal-title":"Cell Res"},{"key":"822_CR21","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","volume":"28","author":"M Zhang","year":"2022","unstructured":"Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma. Clin Cancer Res. 2022;28:2830\u201343.","journal-title":"Clin Cancer Res"},{"key":"822_CR22","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1200\/JCO.21.00389","volume":"39","author":"J Pan","year":"2021","unstructured":"Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39:3340\u201351.","journal-title":"J Clin Oncol"},{"key":"822_CR23","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24:1499\u2013503.","journal-title":"Nat Med"},{"key":"822_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","volume":"19","author":"P Brown","year":"2021","unstructured":"Brown P, Shah B, Advani A, Aoun P, Boyer M, Burke P, et al. Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19:1079\u2013109.","journal-title":"J Natl Compr Cancer Netw"},{"key":"822_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"D Lee","year":"2019","unstructured":"Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"822_CR26","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1046\/j.1365-2141.1997.1112925.x","volume":"97","author":"PA Rowlings","year":"1997","unstructured":"Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97:855\u201364.","journal-title":"Br J Haematol"},{"key":"822_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D, et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021;14:161.","journal-title":"J Hematol Oncol"},{"key":"822_CR28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713\u201322.","journal-title":"Blood."},{"key":"822_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481:157\u201363.","journal-title":"Nature."},{"key":"822_CR30","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3324\/haematol.2011.043919","volume":"96","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kern W, Harbich S, Alpermann T, Jeromin S, Schnittger S, et al. Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia. Haematologica. 2011;96:1874\u20137.","journal-title":"Haematologica."},{"key":"822_CR31","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1182\/blood-2001-11-0093","volume":"100","author":"P Ballerini","year":"2002","unstructured":"Ballerini P, Blaise A, Busson-Le Coniat M, Su XY, Zucman-Rossi J, Adam M, et al. HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood. 2002;100:991\u20137.","journal-title":"Blood."},{"key":"822_CR32","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2020005381","volume":"137","author":"T Khanam","year":"2021","unstructured":"Khanam T, Sandmann S, Seggewiss J, Ruether C, Zimmermann M, Norvil AB, et al. Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance. Blood. 2021;137:2347\u201359.","journal-title":"Blood."},{"key":"822_CR33","doi-asserted-by":"publisher","first-page":"914959","DOI":"10.3389\/fimmu.2022.914959","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Zhou F, Wu Z, Li Y, Li C, Du M, et al. Timing of tocilizumab administration under the guidance of IL-6 in CAR-T therapy for R\/R acute lymphoblastic leukemia. Front Immunol. 2022;13:914959.","journal-title":"Front Immunol"},{"key":"822_CR34","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-14-2888","volume":"21","author":"N Daver","year":"2015","unstructured":"Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, et al. A phase I\/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Clin Cancer Res. 2015;21:2704\u201314.","journal-title":"Clin Cancer Res"},{"key":"822_CR35","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/10428194.2019.1691195","volume":"61","author":"W Guan","year":"2020","unstructured":"Guan W, Jing Y, Dou L, Wang M, Xiao Y, Yu L. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma\/leukemia. Leuk Lymphoma. 2020;61:855\u201361.","journal-title":"Leuk Lymphoma"},{"key":"822_CR36","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.4049\/jimmunol.170.5.2349","volume":"170","author":"E Aandahl","year":"2003","unstructured":"Aandahl E, Sandberg J, Beckerman K, Task\u00e9n K, Moretto W, Nixon D. CD7 is a differentiation marker that identifies multiple CD8 T cell effector subsets. J Immunol. 2003;170:2349\u201355.","journal-title":"J Immunol"},{"key":"822_CR37","doi-asserted-by":"publisher","first-page":"e20191247","DOI":"10.1084\/jem.20191247","volume":"217","author":"J Pol","year":"2020","unstructured":"Pol J, Caudana P, Paillet J, Piaggio E, Kroemer G. Effects of interleukin-2 in immunostimulation and immunosuppression. J Exp Med. 2020;217:e20191247.","journal-title":"J Exp Med"},{"key":"822_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bjh.17662","volume":"194","author":"MR Hines","year":"2021","unstructured":"Hines MR, Keenan C, Maron Alfaro G, Cheng C, Zhou Y, Sharma A, et al. Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021;194:701\u20137.","journal-title":"Br J Haematol"},{"key":"822_CR39","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein DA, Schischlik F, Shao L, Steinberg SM, Yates B, Wang H-W, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138:2469\u201384.","journal-title":"Blood."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00822-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00822-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00822-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T23:36:39Z","timestamp":1682379399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00822-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["822"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00822-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2305563\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,25]]},"assertion":[{"value":"23 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AHC is a founding member of Shanghai YaKe Biotechnology Ltd, a biotechnology company focusing on research and development of tumor cellular immunotherapy. YLZ is employed in Shanghai YaKe Biotechnology Ltd, DW is employed in Beijing GoBroad Hospital Management Co. Ltd and the other authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}